Kiniksa Pharmaceuticals - Class A Share Price Today
Kiniksa Pharmaceuticals - Class A opened higher at $95.85, compared with its previous close of $95.76. In the last trading session, the stock traded between $94.32 and $96.67. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Kiniksa Pharmaceuticals - Class A is now worth
$ 727.49
Giving a profit of
$ 627.49 (627.49%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.56 (+0.58%)
Day High
$96.67
Day Low
$94.32
Day Open
$95.85
Prev Close
$95.76
Volume
2,79,561
1W Return
0.31%
1M Return
21.46%
3M Return
23.74%
6M Return
65.02%
1Y Return
137.42%
Fundamentals
Market Cap ($ Mn)
4,704
PE Ratio
78.87
PB Ratio
9.31
PEG Ratio
0.03
ROE
11.83%
ROCE
16.23%
EPS (TTM)
$0.60
Investment Returns
1 Week
0.31%
1 Month
21.46%
3 Months
23.74%
6 Months
65.02%
9 Months
114.14%
Financials
Quarterly
All values in $ Mn
156.8
Jun 25
180.9
Sep 25
202.1
Dec 25
214.3
Mar 26
243.6
Jun 26
286.0
Sep 26
Updates
28Oct
Goldman Sachs lifts Kiniksa Pharmaceuticals price target to $101
Goldman Sachs maintains a Buy rating on Kiniksa Pharmaceuticals. Price target raised from $90 to $101. Analyst Paul Choi issued the revised rating and target.
15 days ago
28Oct
Wedbush raises Kiniksa Pharmaceuticals price target to $102
Wedbush raised Kiniksa Pharmaceuticals price target from $99 to $102. Wedbush maintains an Outperform rating on the stock. Analyst David Nierengarten led the recent revision. Wells Fargo previously raised its target to $110 with an Overweight rating.
15 days ago
27Oct
Kiniksa Pharmaceuticals Q3FY26 Results: EPS $0.56 beats estimate by 51%
Q3FY26 EPS of $0.56 beat consensus estimates by 51.35%. Quarterly sales rose 58.12% YoY to $285.97 million. Full-year 2026 sales guidance raised to $1.045-$1.05 billion. Arcalyst penetration in multiple-recurrence patients reached 23%. KPL-387 Phase 3 data expected in H2 2027; KPL-1161 Phase 1 starts by year-end.
16 days ago
5Sep
Kiniksa to present at Wells Fargo 21st Annual Healthcare Conference
Management to present at Wells Fargo 21st Annual Healthcare Conference. Fireside chat scheduled for September 9, 2026, at 8:45 am ET. Live webcast and replay available via company website.
2mo ago
8Aug
Kiniksa Pharmaceuticals to present at Canaccord Genuity conference
Kiniksa Pharmaceuticals International, plc will host a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The session begins at 9:00 a.m. Eastern Time and will be webcast live on the company's website. A replay will follow within 48 hours.
Kiniksa Pharmaceuticals beat Q2 earnings and revenue estimates with EPS of $0.30 and sales of $243.6 million, driven by ARCALYST growth. The company raised full-year guidance and reported positive clinical data for pipeline asset KPL-387.
